| Trial ID: | L4391 |
| Source ID: | NCT04965506
|
| Associated Drug: |
Ibi362
|
| Title: |
A Study of IBI362 in Chinese Patients With Type 2 Diabetes
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes
|
| Interventions: |
DRUG: IBI362|OTHER: placebo|OTHER: Dulaglutide
|
| Outcome Measures: |
Primary: The change in HbA1c from baseline to 20 weeks, Baseline,20 weeks | Secondary: Percentage of Participants Achieving HbA1c Target of <7.0%, Baseline,20 weeks|Number of participants with treatment-related adverse events, Baseline,25 weeks
|
| Sponsor/Collaborators: |
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE2
|
| Enrollment: |
252
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2021-09-06
|
| Completion Date: |
2022-06-11
|
| Results First Posted: |
|
| Last Update Posted: |
2023-12-27
|
| Locations: |
China Japan Friendship Hospital, Beijing, Beijing, 100029, China
|
| URL: |
https://clinicaltrials.gov/show/NCT04965506
|
